Zhiyun Zheng Du

Han Kun • Opinion | Hot Spot Tracking: Daily Regulatory Risk Warnings For Drug Clinical Trial Institutions

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Achievements Of Our Country's Drug Review And Approval System Reform (Part 1)

Han Kun • Opinion | Settle The Dust Or Let The Bullets Fly: Biden Administration Signs Executive Order On Promoting Biotechnology And Biomanufacturing Innovation

Han Kun • Opinion | Finally Waiting For You - Interpreting The New Policy Of Cross-border Contract Production Of Drugs And Medical Devices In The Guangdong-Hong Kong-Macao Greater Bay Area

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Of Our Country's Drug Review And Approval System (Part II)

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Achievements Of Our Country's Drug Review And Approval System (Part II)

汉坤 • 观点 | 医药BD项目如何友好"分手"？

Han Kun • Opinion | The New Ethical Review Regulations Focus On Quick Comments

Han Kun • Opinion | Hainan Boao Lecheng Clinical Urgently Needs A Review Of The Highlights Of The New Regulations On The Management Of Imported Drugs And Devices

Han Kun • Opinion | Key Points For The Supervision Of Medical And Three-Product And One-Device Advertising Under The New Regulations On Internet Advertising

Han Kun • Opinion | Brief Review Of The Measures For The Review Of Science And Technology Ethics (Trial) (Draft For Comments)

汉坤 • 观点 | CAR-T/NK监管路在何方 — 体细胞临床研究工作指引（征求意见稿）要点解读

Han Kun • Opinion | Interpretation Of The New Administrative Guidelines For Human Genetic Resources

Han Kun • Opinion | Implementation And Regulation Of DCT (Decentralized Clinical Trials) In China

汉坤 • 观点 | LDT试点新规解读

Han Kun • Opinion | Blockbuster Debut: Interpretation Of The Key Points Of The Implementation Rules Of The Regulations On The Management Of Human Genetic Resources

Han Kun • Opinion | The Spring Of Traditional Chinese Medicine? From The "Special Provisions On The Registration And Administration Of Traditional Chinese Medicines", The Characteristic Marketing Evaluation System Of Traditional Chinese Medicine

药企出海新热点：管线分拆"SON"模式的实践解读

Han Kun Opinion | Breaking News: 10 Questions And Answers On Pharmaceutical Anti-Corruption In 2023

Han Kun Opinion | CAR-T/NK Regulatory Decisions — Interpreting The "Guidelines For Somatic Cell Clinical Research (Trial)"